Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-03-08 (morningstar.se)
5 shares with the largest reductions of estimated fair value after the Q4 result
Stmicroelectronics and Biogen are among the shares that have the largest reductions.
Read more
2025-02-19 (thebionews.net)
Global pharmaceutical company January acquisition. J & J · GSK · Lily Deal, Biogen and Posun Musan <Technology Transfer · Investment · IPO <Article Text-
[The Bio Yu -eun reporter] The global pharmaceutical industry has been mixed with the achievement of January. During the opening period of the 43rd JP Morgan Healthcare Conference 2025 (hereinafter referred to as JP Morgan), the world's largest bio investment event, the news of M & A of multinational pharmaceutical company Johnson and Johnson (J & J) is delivered.
Read more
2025-02-11 (allnews.ch)
Healthcare: acquisitions, innovations & achievements |
At the J.P. Morgan Healthcare 2025 conference held in San Francisco in January, the Biopharma and Medtech sectors presented remarkable progress.
Read more
2025-02-09 (marketbeat.com)
Biogen (BIIB) Expected to Announce Earnings on Wednesday
Biogen (NASDAQ:BIIB) will be releasing earnings before the market opens on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=658031)
Read more
2025-02-04 (marketbeat.com)
Biogen (BIIB) to Release Earnings on Tuesday |
Biogen (NASDAQ:BIIB) will be releasing earnings before the market opens on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=658031)
Read more![[JP Morgan] Biogen ‘No M&A for the time being’… Alzheimer's drug 'Lechembe' expected to do well < Zoom in on academic conference < Text of article -](https://images.businessradar.com/articles/de417211-5459-473e-8894-cc3efad60457)
2025-01-17 (thebionews.net)
[JP Morgan] Biogen ‘No M&A for the time being’… Alzheimer's drug 'Lechembe' expected to do well < Zoom in on academic conference < Text of article -
[The Bio Reporter Seong Jae-jun] Biogen, a multinational pharmaceutical company, has confirmed that it will not engage in mergers and acquisitions (M&A) for the time being. This appears to be a reason to be more cautious in utilizing capital in a situation where products launched last year, such as a treatment for Alzheimer's disease, are expected to do well. Chris Viehb
Read more
2025-01-16 (hitnews.co.kr)
JPM 2025 | Biogen, a latecomer, competes against Alzheimer's disease with Lechembe < Global < Text of article -
On the second day of the 2025 JP Morgan Healthcare Conference, the Alzheimer's disease treatment market emerged as a major topic. Biogen announced its next-generation treatment strategy at the conference and expressed confidence in its fight against strong competitor Eli Lilly. In particular, the key card that Biogen put forward to strengthen its position in the Alzheimer's disease treatment market was 'LEQEMBI'. According to major foreign media, Biogen CEO Christopher Viehbacher said, "Do not underestimate your competitors. “I won’t,” he said, acknowledging Lily’s influence.
Read more
2025-01-15 (biospace.com)
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More -
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”
Read more
2024-12-03 (reuters.com)
Biogen expects steady growth for Alzheimer's drug Leqembi in near term |
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on Tuesday.
Read more